cadonilimab
akesobio
['cadonilimab', 'akeso ']
the 2-year updated data from cadonilimab-1l treatment for g/gej adenocarcinoma was released at the american society of clinical oncology (asco) meeting. in pd-l1 cps &lt;1 population, the median os reached 17.64 months and the median pfs was 8.18 months. 
We are dedicated to the research, development, manufacturing and commercialization of novel antibody drugs that are affordable to patients worldwide.
#9926.HK